nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGDR2—brain—Gilles de la Tourette syndrome	0.0876	0.103	CbGeAlD
Sulindac—AKR1B1—midbrain—Gilles de la Tourette syndrome	0.0741	0.0874	CbGeAlD
Sulindac—AKR1B1—nervous system—Gilles de la Tourette syndrome	0.0609	0.0718	CbGeAlD
Sulindac—AKR1B1—central nervous system—Gilles de la Tourette syndrome	0.0586	0.0692	CbGeAlD
Sulindac—PPARD—midbrain—Gilles de la Tourette syndrome	0.0582	0.0687	CbGeAlD
Sulindac—MAPK3—midbrain—Gilles de la Tourette syndrome	0.0537	0.0633	CbGeAlD
Sulindac—PPARD—nervous system—Gilles de la Tourette syndrome	0.0479	0.0565	CbGeAlD
Sulindac—AKR1B1—brain—Gilles de la Tourette syndrome	0.0465	0.0549	CbGeAlD
Sulindac—PPARD—central nervous system—Gilles de la Tourette syndrome	0.0461	0.0544	CbGeAlD
Sulindac—MAPK3—nervous system—Gilles de la Tourette syndrome	0.0441	0.0521	CbGeAlD
Sulindac—MAPK3—central nervous system—Gilles de la Tourette syndrome	0.0425	0.0501	CbGeAlD
Sulindac—PPARD—brain—Gilles de la Tourette syndrome	0.0366	0.0432	CbGeAlD
Sulindac—MAPK3—brain—Gilles de la Tourette syndrome	0.0337	0.0398	CbGeAlD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.028	0.184	CbGpPWpGaD
Sulindac—SLC22A6—brain—Gilles de la Tourette syndrome	0.0258	0.0304	CbGeAlD
Sulindac—ALB—brain—Gilles de la Tourette syndrome	0.0161	0.019	CbGeAlD
Sulindac—PTGS2—midbrain—Gilles de la Tourette syndrome	0.0139	0.0165	CbGeAlD
Sulindac—CYP1A1—nervous system—Gilles de la Tourette syndrome	0.0137	0.0161	CbGeAlD
Sulindac—CYP1A1—central nervous system—Gilles de la Tourette syndrome	0.0131	0.0155	CbGeAlD
Sulindac—PTGS1—nervous system—Gilles de la Tourette syndrome	0.012	0.0142	CbGeAlD
Sulindac—PTGS1—central nervous system—Gilles de la Tourette syndrome	0.0115	0.0136	CbGeAlD
Sulindac—PTGS2—nervous system—Gilles de la Tourette syndrome	0.0115	0.0135	CbGeAlD
Sulindac—PTGS2—central nervous system—Gilles de la Tourette syndrome	0.011	0.013	CbGeAlD
Sulindac—CYP1A1—brain—Gilles de la Tourette syndrome	0.0104	0.0123	CbGeAlD
Sulindac—PTGS1—brain—Gilles de la Tourette syndrome	0.00917	0.0108	CbGeAlD
Sulindac—PTGS2—brain—Gilles de la Tourette syndrome	0.00876	0.0103	CbGeAlD
Sulindac—MAPK3—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.00683	0.0448	CbGpPWpGaD
Sulindac—MAPK3—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.00649	0.0426	CbGpPWpGaD
Sulindac—MAPK3—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.00636	0.0417	CbGpPWpGaD
Sulindac—PTGDR2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00497	0.0326	CbGpPWpGaD
Sulindac—PTGDR2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00483	0.0317	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00461	0.0303	CbGpPWpGaD
Sulindac—PTGDR2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.0045	0.0295	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00448	0.0294	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00448	0.0294	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00417	0.0274	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00395	0.0259	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00384	0.0252	CbGpPWpGaD
Sulindac—MAPK3—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.00378	0.0248	CbGpPWpGaD
Sulindac—PPARD—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00376	0.0247	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00358	0.0234	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-1-mediated signaling events—MET—Gilles de la Tourette syndrome	0.00346	0.0227	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00301	0.0197	CbGpPWpGaD
Sulindac—PTGDR2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00292	0.0192	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00292	0.0192	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00272	0.0179	CbGpPWpGaD
Sulindac—MAPK3—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.00261	0.0171	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0025	0.0164	CbGpPWpGaD
Sulindac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00247	0.0162	CbGpPWpGaD
Sulindac—MAPK3—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.00191	0.0125	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00191	0.0125	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.00187	0.0123	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0017	0.0112	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00165	0.0108	CbGpPWpGaD
Sulindac—PPARD—Metabolism—HDC—Gilles de la Tourette syndrome	0.00162	0.0106	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00155	0.0101	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00154	0.0101	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0015	0.00984	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.0014	0.00916	CbGpPWpGaD
Sulindac—SLC22A6—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00112	0.00735	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00108	0.00707	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000979	0.00642	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000971	0.00636	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000913	0.00599	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000886	0.00581	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000825	0.00541	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MET—Gilles de la Tourette syndrome	0.000623	0.00409	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000621	0.00407	CbGpPWpGaD
Sulindac—ALB—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000583	0.00382	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000578	0.00379	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00057	0.00374	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000493	0.00323	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000445	0.00292	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000443	0.00291	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000437	0.00287	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00043	0.00282	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000401	0.00263	CbGpPWpGaD
Sulindac—ALB—Metabolism—HDC—Gilles de la Tourette syndrome	0.000399	0.00261	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000296	0.00194	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000281	0.00184	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000279	0.00183	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000262	0.00172	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000254	0.00167	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000237	0.00155	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000166	0.00109	CbGpPWpGaD
